Assessing seroprevalence to adeno-associated virus serotype 9 (AAV9) in preparation for RIDGE™-1, a phase 1b first-in-human study to evaluate safety and efficacy of TN-401 investigational gene therapy in adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC)

IF 1.3 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of electrocardiology Pub Date : 2024-07-01 DOI:10.1016/j.jelectrocard.2024.06.014

Natalia Paterson , Hugh Calkins , Vasanth Vedentham , Neal K. Lakdawala , Wilson Tang Wai Hong , John R. Giudicessi , Matthew R.G. Taylor , Antonis Pantazis , Larry A. Chinitz , Perry Mark Elliott , Phillippe Chevalier , Jeff Haroldson , Whedy Wang , Gretchen Argast , Whit Tingely , Matt Pollman

引用次数: 0

查看原文本刊更多论文

评估 9 号腺病毒血清型 (AAV9) 的血清流行率，为 RIDGE™-1 做准备，RIDGE™-1 是一项 1b 期首次人体试验，目的是评估 TN-401 基因疗法在 PKP2 相关性致心律失常性右室心肌病 (ARVC) 成人患者中的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of electrocardiology 医学-心血管系统

CiteScore

2.70

自引率

7.70%

发文量

152

审稿时长

38 days

期刊介绍： The Journal of Electrocardiology is devoted exclusively to clinical and experimental studies of the electrical activities of the heart. It seeks to contribute significantly to the accuracy of diagnosis and prognosis and the effective treatment, prevention, or delay of heart disease. Editorial contents include electrocardiography, vectorcardiography, arrhythmias, membrane action potential, cardiac pacing, monitoring defibrillation, instrumentation, drug effects, and computer applications.